3. Patient underwent at least 3 consecutive Intravitreal anti VEGF injections of the same kind , Ranibizumab (Lucentis) or Bevacizumab (Avastin) in the study eye during the past 20 weeks and have sub retinal or intraretinal fluid at day 1, as found in OCT examination.